6533b85efe1ef96bd12bfdac
RESEARCH PRODUCT
Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.
Serena MeravigliaR De LucaLivio BlasiGiuseppe CiceroA Maioranasubject
OncologyMalemedicine.medical_specialtymedicine.medical_treatmentT cellelderly patients03 medical and health sciences0302 clinical medicineImmune systemmelanoma metastaticAntineoplastic Agents ImmunologicalInternal medicinemedicineHumans030212 general & internal medicineNeoplasm MetastasisMelanomaAgedbiologybusiness.industryMelanomaclinical benefitlactate dehydrogenaseImmunotherapymedicine.diseaseConfidence intervalelderly patientmedicine.anatomical_structureNivolumabTolerability030220 oncology & carcinogenesisbiology.proteinQuality of LifeFemaleOriginal ArticleImmunotherapyNivolumabAntibodybusinessdescription
Nivolumab is an anti&ndash
year | journal | country | edition | language |
---|---|---|---|---|
2020-05-01 | Current oncology (Toronto, Ont.) |